When administrated to the B16F10 tumor-bearing mice, Roxyl-WL can inhibit IDO1 activity, suppress the tumor growth, reduce the number of Foxp3+ Tregs, and decrease the Kyn/Trp ratio evidently. Here, IDO1 is linked to neoplasm.